MMN: From Immunological Cross-Talk to Conduction Block

[1]  Raymond D. Schellevis,et al.  Fcγ receptor IIIA genotype is associated with rituximab response in antimyelin-associated glycoprotein neuropathy , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[2]  H. Willison,et al.  The pre‐synaptic motor nerve terminal as a site for antibody‐mediated neurotoxicity in autoimmune neuropathies and synaptopathies , 2014, Journal of anatomy.

[3]  H. Franssen,et al.  Pathophysiology of immune‐mediated demyelinating neuropathies—Part II: Neurology , 2013, Muscle & nerve.

[4]  H. Willison,et al.  Glycolipid antigens and autoantibodies in autoimmune neuropathies. , 2013, Trends in immunology.

[5]  T. Kanda,et al.  Sera from patients with multifocal motor neuropathy disrupt the blood-nerve barrier , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[6]  L. Musset,et al.  Sensitivity and predictive value of anti-GM1/galactocerebroside IgM antibodies in multifocal motor neuropathy , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[7]  L. H. van den Berg,et al.  Pharmacokinetics of intravenous immunoglobulin in multifocal motor neuropathy , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[8]  G. Kalna,et al.  Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy , 2013, European journal of neurology.

[9]  J. Puck,et al.  Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. , 2012, The Journal of allergy and clinical immunology.

[10]  H. Akiyama,et al.  FUS/TLS-Immunoreactive Neuronal and Glial Cell Inclusions Increase With Disease Duration in Familial Amyotrophic Lateral Sclerosis With an R521C FUS/TLS Mutation , 2012, Journal of neuropathology and experimental neurology.

[11]  L. Alfredsson,et al.  Very high levels of anti-citrullinated protein antibodies are associated with HLA-DRB1*15 non-shared epitope allele in patients with rheumatoid arthritis. , 2012, Arthritis and rheumatism.

[12]  H. Franssen,et al.  Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies , 2012, Nature Reviews Neurology.

[13]  L. H. van den Berg,et al.  Associated autoimmune diseases in patients with multifocal motor neuropathy and their family members , 2011, Journal of Neurology.

[14]  H. Willison,et al.  An open label clinical trial of complement inhibition in multifocal motor neuropathy , 2011, Journal of the peripheral nervous system : JPNS.

[15]  N. Yuki,et al.  Keeping it simple: is there a need for the various subtyping of axonal forms of Guillain–Barré syndrome? , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[16]  D. Lingwood,et al.  Cholesterol modulates glycolipid conformation and receptor activity. , 2011, Nature chemical biology.

[17]  C. Karam.  Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy , 2010, Neurology.

[18]  Kazuro Furukawa,et al.  Neuromuscular synaptic transmission in aged ganglioside-deficient mice , 2011, Neurobiology of Aging.

[19]  T. Kanda,et al.  Peripheral nerve pericytes modify the blood–nerve barrier function and tight junctional molecules through the secretion of various soluble factors , 2011, Journal of cellular physiology.

[20]  M. Jansen,et al.  IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN , 2010, Journal of Neuroimmunology.

[21]  L. H. van den Berg,et al.  Multifocal motor neuropathy , 2010, Neurology.

[22]  D. Cornblath,et al.  An open‐label trial of rituximab (Rituxan®) in multifocal motor neuropathy , 2010, Journal of the peripheral nervous system : JPNS.

[23]  L. H. van den Berg,et al.  Cold paresis in multifocal motor neuropathy , 2010, Journal of Neurology.

[24]  H. Willison,et al.  Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. , 2010, Brain : a journal of neurology.

[25]  A. Pestronk,et al.  Motor neuropathies and serum IgM binding to NS6S heparin disaccharide or GM1 ganglioside , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[26]  D. Bertrand,et al.  Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy , 2010, Journal of the Neurological Sciences.

[27]  W. Hop,et al.  Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain‐Barré syndrome , 2009, Annals of neurology.

[28]  L. H. van den Berg,et al.  Subcutaneous immunoglobulin therapy for multifocal motor neuropathy , 2009, Journal of the peripheral nervous system : JPNS.

[29]  K. Hirata,et al.  Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain–Barré syndrome , 2008, Journal of Neuroimmunology.

[30]  J. Verschuuren,et al.  Neuromuscular synaptic function in mice lacking major subsets of gangliosides , 2008, Neuroscience.

[31]  L. H. van den Berg,et al.  Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial. , 2007, Brain : a journal of neurology.

[32]  K. Hirata,et al.  Gangliosides contribute to stability of paranodal junctions and ion channel clusters in myelinated nerve fibers , 2007, Glia.

[33]  K. Hirata,et al.  Anti-GM1 Antibodies Cause Complement-Mediated Disruption of Sodium Channel Clusters in Peripheral Motor Nerve Fibers , 2007, The Journal of Neuroscience.

[34]  N. Yuki,et al.  Leukocyte and complement activation by GM1-specific antibodies is associated with acute motor axonal neuropathy in rabbits , 2007, Journal of Neuroimmunology.

[35]  M. Swash,et al.  Multifocal motor neuropathy , 2006, Neurology.

[36]  H. Willison,et al.  Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome , 2005, Annals of neurology.

[37]  A. Priori,et al.  Pathophysiological heterogeneity of conduction blocks in multifocal motor neuropathy. , 2005, Brain : a journal of neurology.

[38]  Kazuro Furukawa,et al.  Overexpression of GD1a Ganglioside Sensitizes Motor Nerve Terminals to Anti-GD1a Antibody-Mediated Injury in a Model of Acute Motor Axonal Neuropathy , 2005, The Journal of Neuroscience.

[39]  P. Dyck,et al.  Multifocal Motor Neuropathy: Pathologic Alterations at the Site of Conduction Block , 2004, Journal of neuropathology and experimental neurology.

[40]  H. Willison,et al.  Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury. , 2003, Brain : a journal of neurology.

[41]  Timothy A. Miller,et al.  Treatment of IgM antibody associated polyneuropathies using rituximab , 2003, Journal of neurology, neurosurgery, and psychiatry.

[42]  Ryuji Kaji,et al.  Physiology of conduction block in multifocal motor neuropathy and other demyelinating neuropathies , 2003, Muscle & nerve.

[43]  L. H. van den Berg,et al.  Demyelination and axonal loss in multifocal motor neuropathy: distribution and relation to weakness. , 2003, Brain : a journal of neurology.

[44]  R. Schnaar,et al.  Localization of major gangliosides in the PNS: implications for immune neuropathies. , 2002, Brain : a journal of neurology.

[45]  A. Priori,et al.  Distinctive abnormalities of motor axonal strength-duration properties in multifocal motor neuropathy and in motor neurone disease. , 2002, Brain : a journal of neurology.

[46]  G. Scarlato,et al.  Multifocal motor neuropathy and Campylobacter jejuni reactivity , 2002, Neurology.

[47]  N. Murray,et al.  Nerve excitability changes in chronic renal failure indicate membrane depolarization due to hyperkalaemia. , 2002, Brain : a journal of neurology.

[48]  D. Gambi,et al.  Anti-GD1a antibodies from an acute motor axonal neuropathy patient selectively bind to motor nerve fiber nodes of Ranvier , 2001, Journal of Neuroimmunology.

[49]  J. A. Titus,et al.  Fragmentation of Immunoglobulin M , 2000, Current protocols in immunology.

[50]  V. Meininger,et al.  Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. , 2001, Brain : a journal of neurology.

[51]  M. Daha,et al.  Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates. , 1999, Annals of neurology.

[52]  L. H. van den Berg,et al.  The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. , 1998, Brain : a journal of neurology.

[53]  A. Pestronk,et al.  Multifocal motor neuropathy , 1997, Neurology.

[54]  R. Nemni,et al.  Motor nerve biopsy studies in motor neuropathy and motor neuron disease , 1997, Muscle & nerve.

[55]  A. Pestronk,et al.  Multifocal motor neuropathy: serum IgM binding to a GM1 ganglioside-containing lipid mixture but not to GM1 alone. , 1997, Neurology.

[56]  A. Windebank,et al.  The sensitivity and specificity of anti-GM sub 1 antibody testing , 1996, Neurology.

[57]  A. Brand,et al.  Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies , 1995, Neurology.

[58]  A. Windebank,et al.  Treatment of stable chronic demyelinating polyneuropathy with 3,4-diaminopyridine. , 1995, Mayo Clinic proceedings.

[59]  J. Månsson,et al.  Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. , 1994, Biochimica et biophysica acta.

[60]  N. Murray,et al.  Failure of 3,4‐diaminopyridine to reverse conduction block in inflammatory demyelinating neuropathies , 1993, Annals of neurology.

[61]  A. Hays,et al.  Localization of GM1 and Gal(β1‐3)GalNAc antigenic determinants in peripheral nerve , 1993, Neurology.

[62]  J. Kimura,et al.  Pathological findings at the site of conduction block in multifocal motor neuropathy , 1993, Annals of neurology.

[63]  K. Nagashima,et al.  Myelin Gangliosides of Human Peripheral Nervous System: An Enrichment of GM1 in the Motor Nerve Myelin Isolated from Cauda Equina , 1992, Journal of neurochemistry.

[64]  F. Mastaglia,et al.  Intravenous immunoglobulin for multifocal motor neuropathy , 1992, The Lancet.

[65]  A. Lugaresi,et al.  Patterns of reactivity of human anti‐GM1 antibodies with spinal cord and motor neurons , 1992, Annals of neurology.

[66]  W. Reinhart,et al.  Effect of high-dose intravenous immunoglobulin therapy on blood rheology , 1992, The Lancet.

[67]  K. Nagashima,et al.  Different Ceramide Compositions of Gangliosides Between Human Motor and Sensory Nerves , 1990, Journal of neurochemistry.

[68]  G. Brewer,et al.  Gangliosides and synaptic transmission. , 1990, Biochimica et biophysica acta.

[69]  R. Auer,et al.  Neuropathy with Onion Bulb Formations and Pure Motor Manifestations , 1989, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[70]  A. Pestronk,et al.  A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside , 1988, Annals of neurology.

[71]  G. Parry,et al.  Multifocal acquired demyelinating neuropathy masqurading as motor neuron disease , 1988, Muscle & nerve.

[72]  D. Chad,et al.  Slow resolution of multifocal weakness and fasciculation , 1986, Neurology.

[73]  M. Magistris,et al.  Motor neuropathy with proximal multifocal persistent conduction block, fasciculations and myokymia. Evolution to tetraplegia. , 1986, European neurology.

[74]  D. Kirschner,et al.  Ganglioside localization on myelinated nerve fibres by cholera toxin binding , 1983, Journal of neurocytology.